Charles River Laboratories completed the acquisition of HemaCare for $380m.

Charles River Laboratories, which provides clinical tests and drug development services, completed the acquisition of HemaCare, which provides customized delivery of biological blood products and services, for $380m. “HemaCare advances the development of life-saving cell therapies through the use of its high-quality cellular products that represent critical inputs to these therapeutics. The addition of HemaCare’s innovative cell therapy products and services to our integrated, early-stage solutions will create a unique, go-to partner for clients to work with Charles River across a comprehensive cell therapy portfolio from idea to novel therapeutic,” James C. Foster, Charles River Laboratories Chairman, President, and Chief Executive Officer.